Adverum Biotechnologies (NASDAQ: ADVM)
Key Data Points
Adverum Biotechnologies Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Adverum Biotechnologies Company Info
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
News & Analysis
Why Adverum Biotechnologies Stock Sank in May
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Why Adverum Biotechnologies Stock Is Imploding Today
Investors are running for the hills following the company's latest clinical update.
3 Best Healthcare Stocks to Buy in May
AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.
Here's Why Adverum Biotechnologies Is Soaring Today
The company's experimental gene therapy for a common cause of blindness showed promise in a clinical trial.
Why Adverum Biotechnologies Stock Is Soaring Today
Adverum's lead gene therapy candidate continues to impress in its early-stage trial.
Here's Why Adverum Biotechnologies Is Soaring Today
Interim results from an early-stage study suggest the company will be competitive the race to develop better treatments for wet age-related macular degeneration.
3 Soaring Biotech Stocks to Watch in December
Here's how they could keep on rocketing higher.
3 Blindness-Fighting Biotech Stocks That Could Surge This Week
Here's what to look out for at the American Academy of Ophthalmology's annual meeting later this week.
Financial Health
General
Q3 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q3 2024 | YoY Change |
---|
Liabilities
Q3 2024 | YoY Change |
---|
Ratios
Q3 2024 | YoY Change |
---|
Cash Flow
Q3 2024 | YoY Change |
---|
Valuation
Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.